- Details
- At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials' findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses ongoin...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Courtney Lawhn Heath emphasizes the complexity of interpreting PSMA PET scans, highlighting the need to recognize common false positives and the limitations of treating PSMA PET as a straightforward diagnostic tool for prostate cancer. Dr. Lawhn Heath advocates for a nuanced approach that integrates anatomical imaging and clinical context to accurately interp...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler discusses the relevance of different PSMA PET agents in clinical practice, emphasizing that while there are various ligands with kidney-dominant or liver-dominant excretion, their clinical impact appears minimal, suggesting PSMA-PET is a unified class of imaging with different logistical aspects. Dr. Fendler highlights the importance of under...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Robert Flavell introduces the basics of PSMA pharmacology and its application in prostate cancer, highlighting the role of PSMA PET in diagnosing high-risk cases and guiding radioligand therapy for metastatic castration-resistant prostate cancer. Dr. Flavell explains the significance of the Glu-Urea-Lys pharmacophore in developing diagnostic and therapeutic a...
|
- Details
- Alicia Morgans interviews Matthew Rettig about the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) within the veterans' healthcare system. Dr. Rettig highlights the VA's infrastructure that supports comprehensive care, including genetic analyses, access to a wide range of medications, and innovative telehealth programs that extend expert care to veterans in...
|
- Details
- Alicia Morgans engages in a conversation with Oliver Sartor about the evolving landscape of Radioligand Therapy in metastatic castration-resistant prostate cancer (mCRPC). Dr. Sartor discusses the trials in progress for each PSMAfore, SPLASH, and ECLIPSE trials. Dr. Sartor notes the trials are not complete and with little to no data the treatments are not yet ready for widespread clinical applicat...
|
- Details
- Jeremie Calais joins Phillip Koo on UroToday where they discuss the first annual PSMA conference hosted by UCLA and UCSF in partnership with Prostate Cancer Foundation. (PCF). The conference topics include PSMA theranostics in prostate cancer and aim to leverage early experiences and global collaborations in PSMA clinical use. It featured a multidisciplinary panel of experts from around the world,...
|
- Details
- Zach Klaassen hosts a discussion with Thomas Hope Jeremie Calais about a conference co-hosted by UCLA and UCSF, focusing on PSMA PET imaging and radioligand therapy. Scheduled for January 18th and 19th, 2024, at UCSF, the conference aims to educate healthcare professionals on interpreting PSMA PET results and managing patients effectively. The target audience includes both academic and private pra...
|
